EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR-TKI, demonstrated in the FLAURA trial, a significant prolonging of PFS and OS relative to first-generation EGFR-TKIs in patients with previously untreated NSCLC [153].